Patents Assigned to Ruprecht-Karls-Universität Heidelberg
-
Patent number: 10413585Abstract: The present invention relates to lipopeptide-based compounds for use in the diagnosis, prevention and/or treatment of a liver disease or condition, preferably liver involved metabolic diseases, as well as in the control or modification of the cholesterol level or cholesterol uptake and, thus, diagnosis, prevention and/or treatment of a cardiovascular disease. The present invention furthermore relates to an in vitro or in vivo assay or method for testing or measuring the NTCP-mediated transport of test compound(s). The present invention furthermore relates to a method for the diagnosis, prevention and/or treatment of a liver disease or condition, comprising administering a therapeutically effective amount of a lipopeptide-based compound to a patient. The present invention furthermore relates to a method for the diagnosis, prevention and/or treatment of a cardiovascular disease.Type: GrantFiled: November 12, 2013Date of Patent: September 17, 2019Assignee: RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERGInventors: Volker Cleeves, Stephan Urban, Ralf Kubitz
-
Publication number: 20190275035Abstract: The present invention relates to the treatment of myocardial infarction, especially to the reduction of tissue damage, the reduction of infarction scars, the improvement of cardiac function, and/or the prevention of congestive heart failure after myocardial infarction. The invention further relates to WNT antagonists, their use in the treatment of myocardial infarction, and to pharmaceutical compositions comprising WNT antagonists.Type: ApplicationFiled: November 6, 2017Publication date: September 12, 2019Applicant: RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERGInventors: Sören MEYER, Florian LEUSCHNER, Hugo KATUS
-
Patent number: 10398791Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).Type: GrantFiled: August 28, 2018Date of Patent: September 3, 2019Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERGInventors: Matthias Eder, Klaus Kopka, Martin Schäfer, Ulrike Bauder-Wüst, Uwe Haberkorn, Michael Eisenhut, Walter Mier, Martina Benesova
-
Patent number: 10393762Abstract: The present invention relates to the field of diagnostic methods. Specifically, the present invention contemplates a method for diagnosing heart failure in a subject, a method for identifying whether a subject is in need for a therapy of heart failure or a method for determining whether a heart failure therapy is successful. The invention also relates to tools for carrying out the aforementioned methods, such as diagnostic devices.Type: GrantFiled: February 1, 2016Date of Patent: August 27, 2019Assignees: METANOMICS GMBH, Ruprecht-Karls-Universitaet HeidelbergInventors: Jens Fuhrmann, Regina Reszka, Juergen Kastler, Kristina Busch, Edgar Leibold, Hugo Katus, Norbert Frey, Johanna Sigl, Tanja Weis
-
Patent number: 10315975Abstract: The present invention relates to a method for the regioselective hydroformylation of polyunsaturated acyclic hydrocarbons, which are 1, 3 butadienes, which, in the 2 position, bear a saturated or monounsaturated or polyunsaturated acyclic hydrocarbon radical. The present invention also relates to the production of secondary products of these hydroformylation products, especially of ambrox.Type: GrantFiled: July 8, 2016Date of Patent: June 11, 2019Assignees: BASF SE, Ruprecht-Karls-Universität HeidelbergInventors: Julia Strautmann, Stefan Rüdenauer, Christian Rein, Melanie Weingarten, Rocco Paciello, Wolfgang Siegel, Michael Breuer, Peter Hofmann, Sebastian Schmidt
-
Patent number: 10316367Abstract: The present invention is directed to methods for diagnosing breast cancer, metastasizing breast cancer, or for determining the CTC status in a subject. Moreover, the present invention is concerned with devices and kits for carrying methods of the invention. The methods comprise determining in a sample of a subject suspected to be afflicted with breast cancer the amount of at least one miRNA selected from a recited list of miRNAs, followed by comparing the amount with one or more references, whereby breast cancer is to be diagnosed.Type: GrantFiled: June 21, 2013Date of Patent: June 11, 2019Assignee: RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERGInventors: Barbara Burwinkel, Katarina Cuk, Manuela Zucknick, Dharanija Madhavan
-
Patent number: 10254273Abstract: The present invention relates to an in vitro method for evaluating the anti- or pro-arrhythmic potential, cardiotoxicity and/or modulation capacity of cardiomyocyte function of compound(s). The present invention also relates to compound(s) identified or evaluated in the method of the invention for use in the treatment of a heart disease. The present invention further relates to the use of the density change of cardiac Nav 1.5 sodium channels in intercalated discs of cardiomyocytes as marker and/or diagnostic for the anti- or pro-arrhythmic potential of a compound, the cardiotoxicity of a compound or modulation capacity of cardiomyocyte function by said compound, and/or in preclinical assessment for cardiac liability of compounds and cardio-safety assessment. The present invention further relates to a kit for evaluating the anti- or pro-arrhythmic potential, cardiotoxicity and/or modulation capacity of cardiomyocyte function of compound(s).Type: GrantFiled: August 11, 2015Date of Patent: April 9, 2019Assignee: RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERGInventors: Michael Koenen, Pessah Yampolsky, Patrick A. Schweizer, Dierk Thomas, Hugo A. Katus
-
Patent number: 10253099Abstract: The present invention relates to conjugates comprising a protein and multivalent cell-penetrating peptide(s), each multivalent cell-penetrating peptide comprising at least two cell-penetrating peptides, wherein the multivalent cell-penetrating peptide(s) is/are covalently attached to the protein. The present invention furthermore relates to a method of generating the conjugates and to their medical uses, in particular their use in the diagnosis, prevention and/or treatment of diseases. The present invention relates to methods of diagnosis, prevention and/or treatment of diseases, comprising administering the conjugates of the invention to a patient.Type: GrantFiled: December 4, 2013Date of Patent: April 9, 2019Assignee: RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERGInventors: Matthias Strieker, Walter Mier, Uwe Haberkorn
-
Publication number: 20190099461Abstract: The present invention relates to a recombinant virus of the family Paramyxoviridae, comprising at least one expressible polynucleotide encoding a multispecific binding polypeptide, said multispecific binding polypeptide comprising a first binding domain binding to a surface molecule of an immune cell with antitumor activity, preferably a lymphocyte, more preferably a T cell or a dendritic cell, and a second binding domain binding to a tumor-associated antigen; to a polynucleotide encoding the same, and to a kit comprising the same. Moreover, the present invention relates to a method for treating cancer in a subject afflicted with cancer, comprising contacting said subject with a recombinant virus of the family Paramyxoviridae of the invention, and thereby, treating cancer in a subject afflicted with cancer.Type: ApplicationFiled: December 13, 2018Publication date: April 4, 2019Applicants: Deutsches Krebsforschungszentrum, RUPRECHT-KARLS-UNIVERSITAET HEIDELBERGInventors: Guy UNGERECHTS, Tobias SPECK, Christine ENGELAND, Sascha BOSSOW
-
Patent number: 10233232Abstract: The present invention relates to a binding polypeptide specifically binding to the amino acid sequence W-V-N-X1-F-Y-X2 (SEQ ID NO: 1), wherein X1 represents any amino acid, preferably Q or P, and wherein X2 represents any amino acid, preferably, T or S in a norovirus polypeptide. The present invention further relates to polynucleotide encoding a binding polypeptide of the present invention an to a host cell comprising the same or the polynucleotide of the invention. The present invention further relates to a method of detecting the presence of a norovirus capsid polypeptide in a sample and to kits, devices, and uses making use of the binding peptide of the invention.Type: GrantFiled: October 14, 2015Date of Patent: March 19, 2019Assignees: Deutsches Krebsforschungszentrum, Ruprecht-Karls-Universität HeidelbergInventors: Grant Hansman, Anna Koromyslova
-
Patent number: 10172894Abstract: The present invention relates to a recombinant virus of the family Paramyxoviridae, comprising at least one expressible polynucleotide encoding a multispecific binding polypeptide, said multispecific binding polypeptide comprising a first binding domain binding to a surface molecule of an immune cell with antitumor activity, preferably a lymphocyte, more preferably a T cell or a dendritic cell, and a second binding domain binding to a tumor-associated antigen; to a polynucleotide encoding the same, and to a kit comprising the same. Moreover, the present invention relates to a method for treating cancer in a subject afflicted with cancer, comprising contacting said subject with a recombinant virus of the family Paramyxoviridae of the invention, and thereby, treating cancer in a subject afflicted with cancer.Type: GrantFiled: August 25, 2016Date of Patent: January 8, 2019Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, RUPRECHT-KARLS-UNIVERSITAET HEIDELBERGInventors: Guy Ungerechts, Tobias Speck, Christine Engeland, Sascha Bossow
-
Patent number: 10119135Abstract: The present invention relates to the identification of microRNAs of the miR-148 family that are involved in the pathogenesis of chronic pulmonary diseases. The present invention relates to micro RNA of the miR-148 family selected from miR-148a, miR-148b and miR-152 for use in the diagnosis, prognosis, prevention and/or therapy of a chronic pulmonary disease. The present invention further relates to miR-148 inhibitors, pharmaceutical compositions comprising such inhibitors, their use in preventing and/or treating chronic pulmonary diseases, and methods for preventing and/or treating chronic pulmonary diseases. The present invention further relates to transgenic, non-human mammals and methods for identifying modulators of miR-148 and methods for diagnosis and/or prognosis of chronic pulmonary diseases.Type: GrantFiled: May 15, 2013Date of Patent: November 6, 2018Assignee: RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERGInventors: Marcus Mall, Raman Agrawal, Martina Muckenthaler
-
Patent number: 10065939Abstract: Compounds of formula (IIc); wherein X3 and X4 independently from each other are N or CR8 wherein R8 may be same or different; Y1, Y2, Y3 and Y4 independently from each other are N or CR9 wherein R9 may be same or different and wherein up to 3 of the group Y1, Y2, Y3 and Y4 may be N; their solvates, hydrates, and pharmaceutically acceptable salts, their use for modulating the Wnt signalling pathway activity and their use as a medicament, preferably for the treatment of cancer.Type: GrantFiled: May 19, 2016Date of Patent: September 4, 2018Assignees: Deutsches Krebsforschungszentrum, Ruprecht-Karls-Universität HeidelbergInventors: Michael Boutros, Rajendra-Prasad Maskey, Corinna Koch, Florian Fuchs, Sandra Steinbrink, Daniel Gilbert
-
Patent number: 10058591Abstract: The present invention relates to a combination of a parvovirus and a cytokine, preferably IFNy, for use in treating pancreatic cancer, in particular a terminal stage of this disease.Type: GrantFiled: December 3, 2015Date of Patent: August 28, 2018Assignees: Deutsches Krebsforschungszentrum, Ruprecht-Karls-Universitaet HeidelbergInventors: Zahari Raykov, Svitlana Grekova, Laurent Daeffler, Jean Rommelaere, Marc Aprahamian, Nathalia Giese
-
Publication number: 20180238914Abstract: The present invention relates to the field of diagnostic methods. Specifically, the present invention contemplates a method for diagnosing a cardiac disease in a subject based on determining the amounts of at least three lipid metabolite biomarkers and at least one further cardiac biomarker. The invention also relates to tools for carrying out the aforementioned methods, such as diagnostic devices.Type: ApplicationFiled: August 19, 2016Publication date: August 23, 2018Applicants: METANOMICS GMBH, RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERGInventors: Philipp Schatz, Henning Witt, Erik Peter, Martin Dostler, Susan Carvalho, Philipp Ternes, Philipp Mappes, Jenny Fischer, Hugo A. Katus, Tanja Weis, Norbert Frey
-
Patent number: 10041070Abstract: The present invention discloses microRNAs (miR) involved in the regulation of the lipid and glucose metabolism. Several conserved miR molecules were found as direct targets of the glucocorticoid hormone/glucocorticoid receptor signaling axis. Hence, the present invention pertains to inhibitors of these miRs—such as antimiRs and blockmiRs—as well as isolated miR molecules or miR expression constructs for the treatment or prevention of metabolic disorders caused by deregulated glucocorticoid signaling, such as insulin resistance, the metabolic syndrome, obesity and/or diabetes type II. Particular preferred embodiments of the invention pertain to antagonists or agonists of a miR of the conserved miR-379-410 cluster, particularly of miR-379.Type: GrantFiled: October 28, 2014Date of Patent: August 7, 2018Assignees: Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts, Ruprecht-Karls-Universität HeidelbergInventors: Mauricio Berriel Diaz, Roldan De Guia, Stephan Herzig
-
Patent number: 10024986Abstract: The invention relates to a neutron detector unit for neutrons, in particular thermal and cold neutrons, comprising a detector housing (7, 17, 27), cathode elements and a plurality of anode elements (5, 15, 25), wherein in order to form a volume detector unit the anode elements (5, 15, 25) and the cathode elements enable a three-dimensional spatial resolution for conversion events, characterized by a converter gas in the detector housing (7, 17, 27). According to the invention, in a neutron detector arrangement which includes at least one neutron detector unit the neutron detector unit (3, 13, 23) or at least one of the neutron detector units (3, 13, 23) is oriented in such a way that at least some of the anode elements (5, 15, 25) of the at least one neutron detector unit (3, 13, 23) extend at least predominantly in a longitudinal orientation parallel or almost parallel to the direction of travel of the neutrons (4) to be detected.Type: GrantFiled: September 13, 2013Date of Patent: July 17, 2018Assignees: Forschungszentrum Juelich GmbH, CDT Cascade Detector Technologies GmbH, Ruprecht-Karls-Universitaet HeidelbergInventors: Peter Lennert, Martin Klein, Christian J. Schmidt, Werner Schweika
-
Patent number: 10016519Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer.Type: GrantFiled: March 20, 2017Date of Patent: July 10, 2018Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRIUM, RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERGInventors: Klaus Kopka, Martina Benesova, Jens Cardinale, Matthias Eder, Martin Schäfer, Ulrike Bauder-Wüst, Uwe Haberkorn, Michael Eisenhut
-
Patent number: 9938580Abstract: The present invention relates to the use of DNA methylation profiles of patient samples for the diagnosis, prognosis and/or therapy monitoring of a heart disease in a patient, wherein the DNA methylation profile of the patient sample is compared with the DNA methylation profile of a control sample, and wherein a difference in the DNA methylation profile of the patient sample compared to the control sample is indicative of a heart disease or of the risk for developing a heart disease or for a prediction of therapy effects or therapy outcome. The present invention further relates to methods for the diagnosis, prognosis and/or therapy monitoring of a heart disease in a patient, comprising determining the DNA methylation profile in a patient sample comprising genomic DNA from heart cells, heart tissue or peripheral blood; and comparing the DNA methylation profile in the patient sample with the DNA methylation profile from a normal subject not having a heart disease or having a normal heart function.Type: GrantFiled: March 14, 2013Date of Patent: April 10, 2018Assignee: RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERGInventors: Benjamin Meder, Jan Haas, Hugo A. Katus
-
Publication number: 20180066317Abstract: The present invention pertains to methods for classifying tumorous diseases based on their specific genomic DNA methylation profile. The invention provides a method that allows for a classification of a tumor sample obtained from a patient by analysing a multitude, preferably genome wide, collection of CpG positions by comparison to a classification rule derived from a set of methylation data acquired from pre-classified tumor species. The invention is in particular useful for classifying brain tumor samples since brain tumors are characterized by a large variety of distinct tumor species which have different prognostic values and require in the clinic a for each species developed treatment regime.Type: ApplicationFiled: September 15, 2016Publication date: March 8, 2018Applicants: Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts, Ruprecht-Karls-Universität HeidelbergInventors: STEFAN PFISTER, ANDREAS VON DEIMLING, DAVID JONES, DAVID CAPPER, VOLKER HOVESTADT, MARTIN SILL, MELANIE BEWERUNGE-HUDLER, MATTHIAS SCHICK